Community Statement: Safeguarding Children against Tuberculosis Takes Center Stage with Introduction of Child-Friendly Formulation of Rifapentine for Short-Course Tuberculosis Preventive Treatment
As community and civil society leaders who have worked determinedly to prevent tuberculosis (TB) in our communities, we herald the introduction of the world’s first child-friendly formulation of rifapentine as
USAID-Funded ACCELERATE Initiative to Boost Tuberculosis Elimination Efforts in South Africa
In a landmark move towards ending tuberculosis (TB) in South Africa, the U.S. Agency for International Development (USAID) has awarded the Aurum Institute US $47 million (approx. R886 million) to
New Study: Combo Treatment Can Help Solve the TB-HIV Co-Infection Crisis — More than Half a Million People Could Benefit
For people starting HIV treatment, combining dolutegravir-containing antiretroviral therapy with 3HP TB preventive treatment is safe and works effectively in tandem
DENVER (March 5, 2023) — New clinical trial
New Child-Friendly Formulation of Rifapentine for Short Course Tuberculosis Prevention Treatment.
Now Available as Unitaid and IMPAACT4TB Launch an Early Market Access Vehicle (EMAV)
More than 2 million children and adolescents lack preventive treatment for TB, which is needed for those
Prof. Gavin Churchyard receives A-rating from National Research Foundation
South Africa’s National Research Foundation has released its rating of researchers as part of its goal to develop an internationally competitive scientific research system. Aurum Group CEO Prof Gavin Churchyard
PanTB-HM Clinical Trial Begins Recruitment in South Africa
The panTB-HM clinical trial has begun patient recruitment in South Africa, with first patient dosed on 28 July 2023. This trial is a historic milestone in the quest to revolutionise